000			02056 a2200577 4500
005			20250516042857.0
264		0	_c20111207
008			201112s 0 0 eng d
022			_a1865-8652
024	7		_a10.1007/s12325-011-0037-x _2doi
040			_aNLM _beng _cNLM
100	1		_aTauber, Shachar
245	0	0	_aMicrobiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. _h[electronic resource]
260			_bAdvances in therapy _cJul 2011
300			_a566-74 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnti-Bacterial Agents _xadministration & dosage
650	0	4	_aAza Compounds _xadministration & dosage
650	0	4	_aChild
650	0	4	_aChild, Preschool
650	0	4	_aConjunctivitis, Bacterial _xdrug therapy
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aFluoroquinolones
650	0	4	_aHaemophilus Infections _xdrug therapy
650	0	4	_aHaemophilus influenzae _xdrug effects
650	0	4	_aHumans
650	0	4	_aInfant
650	0	4	_aMale
650	0	4	_aMicrobial Sensitivity Tests
650	0	4	_aMiddle Aged
650	0	4	_aMoxifloxacin
650	0	4	_aOphthalmic Solutions _xadministration & dosage
650	0	4	_aPneumococcal Infections _xdrug therapy
650	0	4	_aQuinolines _xadministration & dosage
650	0	4	_aStaphylococcal Infections _xdrug therapy
650	0	4	_aStaphylococcus aureus _xdrug effects
650	0	4	_aStreptococcus pneumoniae _xdrug effects
650	0	4	_aYoung Adult
700	1		_aCupp, Gale
700	1		_aGarber, Richard
700	1		_aBartell, John
700	1		_aVohra, Firoz
700	1		_aStroman, David
773	0		_tAdvances in therapy _gvol. 28 _gno. 7 _gp. 566-74
856	4	0	_uhttps://doi.org/10.1007/s12325-011-0037-x _zAvailable from publisher's website
999			_c20936279 _d20936279